{"id":"mfolfox-6","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Mucositis"},{"rate":"30-40","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1298","moleculeType":"Small molecule","molecularWeight":"440.58"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"mFOLFOX6 (modified FOLFOX6) is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin (folinic acid) enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA cross-links to trigger cell death. This triplet combination is designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"mFOLFOX6 is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:09.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05179889","phase":"PHASE2, PHASE3","title":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","status":"RECRUITING","sponsor":"Chungnam National University Hospital","startDate":"2021-07-06","conditions":"Colon Cancer Stage III","enrollment":308},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":"Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":236},{"nctId":"NCT06109467","phase":"PHASE2","title":"Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-01-12","conditions":"GastroEsophageal Cancer, Gastric Cancer","enrollment":36},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":"Locally Advanced Rectal Carcinoma","enrollment":126},{"nctId":"NCT04130854","phase":"PHASE2","title":"INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-04-24","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":58},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT06722183","phase":"PHASE2","title":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-16","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT07235930","phase":"PHASE3","title":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-15","conditions":"Non-Resectable Pancreas Carcinoma","enrollment":292},{"nctId":"NCT02967289","phase":"PHASE3","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-27","conditions":"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)","enrollment":792},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT03647969","phase":"PHASE2","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-07","conditions":"Adenocarcinoma of the Stomach, GastroEsophageal Cancer","enrollment":262},{"nctId":"NCT05954078","phase":"PHASE3","title":"Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-01","conditions":"High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation","enrollment":340},{"nctId":"NCT06393166","phase":"PHASE2","title":"Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-05-01","conditions":"Non-Resectable Pancreas Carcinoma","enrollment":37},{"nctId":"NCT04543695","phase":"PHASE2","title":"A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rectal Cancer","enrollment":255},{"nctId":"NCT03503630","phase":"PHASE2","title":"Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Ali Shamseddine","startDate":"2018-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":44},{"nctId":"NCT05984485","phase":"PHASE3","title":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-05","conditions":"Rectal Cancer","enrollment":766},{"nctId":"NCT05948072","phase":"PHASE3","title":"Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":250},{"nctId":"NCT05116891","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-09-22","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03231722","phase":"PHASE3","title":"First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2017-09-13","conditions":"Metastatic Colorectal Cancer","enrollment":435},{"nctId":"NCT00819780","phase":"PHASE2","title":"PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-04-24","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":285},{"nctId":"NCT05484024","phase":"PHASE2, PHASE3","title":"Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-08-06","conditions":"Rectal Neoplasms Malignant, Radiotherapy","enrollment":588},{"nctId":"NCT05468177","phase":"PHASE2","title":"Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2022-08-01","conditions":"Colonic Neoplasms","enrollment":66},{"nctId":"NCT05353582","phase":"PHASE2","title":"Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":168},{"nctId":"NCT04370418","phase":"PHASE2, PHASE3","title":"Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-05-01","conditions":"Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum","enrollment":8},{"nctId":"NCT02934464","phase":"PHASE3","title":"Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-12","conditions":"Stomach Neoplasms","enrollment":280},{"nctId":"NCT04747951","phase":"PHASE4","title":"Total Neoadjuvant Therapy in Rectal Cancer Treatment","status":"UNKNOWN","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2020-10-30","conditions":"Rectal Cancer","enrollment":280},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT03975049","phase":"PHASE3","title":"Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2019-08","conditions":"Rectal Cancer, Chemotherapy Effect","enrollment":933},{"nctId":"NCT01632722","phase":"PHASE2","title":"Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-06","conditions":"Colorectal Cancer, Liver Metastasis","enrollment":79},{"nctId":"NCT01157039","phase":"PHASE2","title":"A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin","status":"WITHDRAWN","sponsor":"AHS Cancer Control Alberta","startDate":"2011-10","conditions":"Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer","enrollment":""},{"nctId":"NCT01164215","phase":"PHASE1","title":"Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-02","conditions":"Colorectal Cancer, Diarrhea, Neutropenia","enrollment":76},{"nctId":"NCT02024412","phase":"PHASE3","title":"Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2013-11","conditions":"Colorectal Cancer","enrollment":240},{"nctId":"NCT02024438","phase":"PHASE3","title":"Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2013-12","conditions":"Gastric Cancer","enrollment":240},{"nctId":"NCT00904839","phase":"PHASE2","title":"BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-05","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT00138177","phase":"PHASE1","title":"Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-07","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer","enrollment":54}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COLON CANCER"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatino + l-leucovorin + 5 Fluorouracile"],"phase":"phase_3","status":"active","brandName":"mFOLFOX 6","genericName":"mFOLFOX 6","companyName":"Chungnam National University Hospital","companyId":"chungnam-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOX6 is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}